Clinical trials: IGA Glomerulonephritis
IgA Nephropathy
Probiotics in IgA Nephropathy
Recent studies have shown an increased gastrointestinal reactivity and increased intestinal permeability in IgA nephropathy (IgAN).
- Trial name
- NCT01781312
- Testing
- ProTectis, Gastrus
- Where
- 3 sites in Sweden
- Volunteers
- 20 people
- Sponsor
- Uppsala University Hospital
IgA Nephropathy (IgAN)
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
IgA nephropathy (IgAN) is a chronic progressive kidney disease, and long-term control of proteinuria and prevention of relapse are crucial for delaying disease progression.
- Trial name
- NeFRIN (NCT07604311)
- Testing
- NEFECON
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Glomerulonephritis, IgAN
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
IgA nephropathy (IgAN) is a histologically defined glomerulonephritis (renal biopsy) by the presence of deposits immunoglobulin A (IgA) in the renal mesangium (at least 1+) by immunofluorescence.
- Trial name
- PIRAT (NCT02523768)
- Testing
- ATG-F, Simulect
- Where
- 15 sites in France
- Volunteers
- 117 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Systemic Lupus Erythematosus, Immunoglobulin A Nephropathy
The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.
The study hypothesis: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical manifestations. Its mechanisms are not well understood.
- Trial name
- NCT05132621
- Testing
- Smear
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Medical University of Warsaw
IGA Nephropathy
"Steroids and Azathioprine Versus Steroids Alone in IgAN"
In a previous trial the investigators found that the effect of steroids in IgA nephropathy diminish over time. The difference in renal survival is striking up till the third year, but then remains constant.
- Trial name
- NCT00755859
- Testing
- steroids plus azathioprine, steroids
- Where
- 28 sites in Italy, Switzerland
- Volunteers
- 206 people
- Sponsor
- A. Manzoni Hospital
Purpura, Schoenlein-Henoch
HSP-glomerulonephritis Trial: MP vs CyA
No curative treatment of severe HSP nephritis is known. Apart from corticosteroids, immunosuppressive drugs, such as azathioprine and cyclophosphamide, have been used to treat severe HSP nephritis.Limited patient series treated…
- Trial name
- NCT00425724
- Testing
- Methylprednisolone pulses plus prednisone versus Cyclosporine A
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Oulu University Hospital
Primary IgA Nephropathy
Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy
The study is being conducted to evaluate the efficacy, and safety of SHR - 2010 injection in patients with primary IgA nephropathy.
- Trial name
- NCT05847920
- Testing
- SHR-2010 Injection
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
IGA Glomerulonephritis
Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy
The estimation of the cardiovascular risk in the general population must take into account small renal disturbances, as the microalbuminuria.
- Trial name
- NCT02527902
- Testing
- Holter
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
IgA Nephropathy (IgAN), Renal and Urinary Disorders
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.
- Conditions
- IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
- Trial name
- ORIGIN EXTEND (NCT06674577)
- Testing
- Atacicept 150 mg
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Vera Therapeutics, Inc.
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just completed an 8 month trial of MMF treatment alone.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446251
- Testing
- Rituximab, Mycophenolate mofetil (MMF)
- Volunteers
- 14 people
- Sponsor
- University of Washington
IgA Nephropathy
IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection
The current prospective, non-interventional study (NIS) being conducted under the IgNITE umbrella protocol using primary data collection (PDC), aims to enhance understanding of real-world patient profiles, treatment patterns, and…
- Trial name
- NCT07481084
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
QLS7305 injection is a chemically synthesized double-stranded small interfering RNA (siRNA) targeting complement C3, covalently linked to a ligand containing N-acetylgalactosamine (GalNAc) residues.
- Conditions
- IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G), Primary Membranous Nephropathy
- Trial name
- NCT07730632
- Testing
- QLS7305 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Treatment Resistant Nephrotic Syndrome
Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)
This study will examine the safety and effectiveness of ACTHAR Gel, when used to treat 15 patients diagnosed with "treatment resistant nephrotic syndrome." Nephrotic syndrome is a group of symptoms that includes low levels of…
- Trial name
- NCT01129284
- Testing
- ACTHAR gel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Primary IgA Nephropathy
A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy
To evaluate the safety and efficacy of Tai Ai(Recombinant Human B Lymphocyte Stimulator Receptor-Antibody Fusion Protein for Injection) in the treatment of IgA nephropathy.
- Trial name
- NCT04291781
- Testing
- RC18 160mg, RC18 240mg
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RemeGen Co., Ltd.
IgA Nephropathy (IgAN)
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
This Phase 3 study will evaluate the safety and efficacy of JADE101 compared with placebo in adults with immunoglobulin A nephropathy (IgAN).
- Trial name
- NCT07902817
- Testing
- JADE101
- Volunteers
- 480 people
- Sponsor
- Jade Biosciences, Inc.
IgA Nephropathy
The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy
This is a single center,prospective,no-controlled clinical trial
- Trial name
- NCT01451710
- Testing
- Prednisone or Prednisolone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing University School of Medicine
IgA Nephropathy, IgAN
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.
- Trial name
- NCT05125068
- Testing
- AT-1501
- Where
- 26 sites in Australia, Croatia and 8 more
- Volunteers
- 24 people
- Sponsor
- Eledon Pharmaceuticals
IgA Nephropathy
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).
- Trial name
- NCT03945318
- Testing
- BION-1301 Single Dose, BION-1301 Multiple Doses
- Where
- 16 sites in United States, South Korea and 1 more
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy
An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
The pathological variants of IgA nephropathy identified by the Oxford classification may be related to the clinical data at presentation and follow-up, including proteinuria and renal function.
- Trial name
- NCT01502579
- Where
- China
- Volunteers
- 603 people
- Sponsor
- Guangdong Provincial People's Hospital
Glomerulonephritis, IGA
Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy
This study aims to investigate the relevance of the Tfh/Tfr (Follicular helper T cells/ Follicular regulatory T cells) ratio in patients with IgA nephropathy: To identify a differential expression of the Tfh/Tfr ratio in patients…
- Trial name
- LYMFONI (NCT05791162)
- Testing
- Blood collection, Urine sample
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon